

REMARKS

The Examiner has indicated that three informal matters prevent allowance of the pending claims in the Application. Specifically, the Examiner has requested that, in claims 36, 49 and 42, the term – further – be added before the word “comprising”. The Applicants have herein amended claims 36, 39, and 42 to include the term “further” before the word “comprising”. The Applicants respectfully request that the Examiner now allow the pending claims.


Based on the foregoing, the Applicants believe that the application is now in condition for allowance and respectfully request early notice to that effect.

If the Examiner deems that additional fees are properly assessable in the case or that certain fees should be refunded, the Examiner is authorized to charge or credit such fees to Deposit Account No. 19-0134 in the name of Novartis Corporation.

If it will advance prosecution of the Application the Examiner is urged to contact the Applicants' undersigned counsel at the telephone number listed below.

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7960

Respectfully submitted,


Edward J. Wilusz, Jr.
Attorney for Applicants
Reg. No. 52,370

Date: June 28, 2005